Table 2.

Assessment of radioiodine-refractory disease criteria of patients with differentiated thyroid carcinoma

Refractoriness criteria
Multiple metastatic lesions, with at least one without RAI uptake in the post-iodine examination	9 (20.5)
Structural disease progression shortly after RAI therapy despite having uptake	5 (11.4)
Lack of remission following a cumulative dose of 600 mCi or more	7 (15.9)
Absence of RAI uptake on scintigraphy following initial RAI therapy	23 (52.3)

Results expressed as n (%).

RAI: radioiodine therapy.